Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives

References

• YangWZhuDGeJPrevalence of diabetes among men and women in ChinaN Engl J Med2008362121090110120335585
   PubMed Web of Science ®Google Scholar
• XuYWangLHeJPrevalence and control of diabetes in Chinese adultsJAMA2013310994895924002281
   PubMed Web of Science ®Google Scholar
• BaileyCJKodackMPatient adherence to medication requirements for therapy of type 2 diabetesInt J Clin Pract201165331432221314869
   PubMed Web of Science ®Google Scholar
• MillerBRNguyenHHuCJLinCNguyenQTNew and emerging drugs and targets for type 2 diabetes: reviewing the evidenceAm Health Drug Benefits20147845246325558307
   PubMedGoogle Scholar
• RaptisSADimitriadisGDOral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizersExp Clin Endocrinol Diabetes2001109Suppl 2S265S28711460577
   PubMedGoogle Scholar
• LebovitzHEDifferentiating members of the thiazolidinedione class: a focus on safetyDiabetes Metab Res Rev200218S2S23S2911921435
   PubMedGoogle Scholar
• McintyreNHoldsworthCDTurnerDSNew interpretation of oral glucose toleranceLancet196427349202114149200
   PubMed Web of Science ®Google Scholar
• ElrickHStimmlerLHladCJJrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• PerleyMJKipnisDMPlasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjectsJ Clin Invest19674612195419626074000
   PubMed Web of Science ®Google Scholar
• DruckerDJPhilippeJJepealLHabenerJFGlucagon gene 5′-flanking sequences promote islet cell-specific gene transcriptionJ Biol Chem19872623215659156653316202
   PubMed Web of Science ®Google Scholar
• OrskovCHolstJJPoulsenSSKirkegaardPPancreatic and intestinal processing of proglucagon in manDiabetologia198730118748813446554
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia19933687417448405741
   PubMed Web of Science ®Google Scholar
• DeaconCFPridalLKlarskovLOlesenMHolstJJGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pigAm J Physiol19962713 Pt 1E458E4648843738
   PubMed Web of Science ®Google Scholar
• HansenLDeaconCFOrskovCHolstJJGlucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestineEndocrinology1999140115356536310537167
   PubMed Web of Science ®Google Scholar
• CuiYMGuoXHZhangDMPharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitusJ Diabetes20135212713523332026
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• EdvellALindströmPInitiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?)Endocrinology199914027787839927305
   PubMed Web of Science ®Google Scholar
• StoffersDAKiefferTJHussainMAInsulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreasDiabetes200049574174810905482
   PubMed Web of Science ®Google Scholar
• GiraltMVergaraPGlucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in ratDig Dis Sci199944232232910063918
   PubMed Web of Science ®Google Scholar
• TolessaTGutniakMHolstJJEfendicSHellstrM PMInhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatinJ Clin Invest199810247647749710445
   PubMed Web of Science ®Google Scholar
• WuHSuiCXuHThe GLP-1 Analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clampJ Diabetes Res2014201452451725580440
   PubMed Web of Science ®Google Scholar
• PerfettiRMerkelPGlucagon-like peptide-1: a major regulator of pancreatic beta-cell functionEur J Endocrinol2000143671772511124853
   PubMed Web of Science ®Google Scholar
• van DijkGThieleTEGlucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stressNeuropeptides199933540641410657518
   PubMed Web of Science ®Google Scholar
• TurtonMDO’SheaDGunnIA role for glucagon-like peptide-1 in the central regulation of feedingNature199637969728538742
   PubMed Web of Science ®Google Scholar
• DruckerDJMinireview: the glucagon-like peptidesEndocrinology2001142252152711159819
   PubMed Web of Science ®Google Scholar
• PadruttILutzTAReuschCEZiniEEffects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy catsRes Vet Sci201599232925648286
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• KoltermanOGBuseJBFinemanMSSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab20038873082308912843147
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLHolstJJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group studyLancet2002359930982483011897280
   PubMed Web of Science ®Google Scholar
• XuWBiYSunZComparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)J Intern Med2015277113715025039675
   PubMed Web of Science ®Google Scholar
• Martin-MontalvoAMerckenEMMitchellSJMetformin improves healthspan and lifespan in miceNat Commun20134219223900241
   PubMed Web of Science ®Google Scholar
• Russell-JonesDCuddihyRMHanefeldMEfficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDiabetes Care201235225225822210563
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
   PubMed Web of Science ®Google Scholar
• AhmadianMSuhJMHahNPPARγ signaling and metabolism: the good, the bad and the futureNat Med201319555756623652116
   PubMed Web of Science ®Google Scholar
• WintersteinAGRosiglitazone and the risk of adverse cardiovascular outcomesClin Pharmacol Ther201189677677821593751
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• MaedlerKCarrRDBoscoDZuelligRABerneyTDonathMYSulfonylurea induced beta-cell apoptosis in cultured human isletsJ Clin Endocrinol Metab200590150150615483097
   PubMed Web of Science ®Google Scholar
• HolsteinAPlaschkeAEgbertsELower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamideDiabetes Metab Res Rev200117646747311757083
   PubMed Web of Science ®Google Scholar
• GallwitzBGuzmanJDottaFExenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trialLancet201237998332270227822683137
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab20063315316516517403
   PubMed Web of Science ®Google Scholar
• TewsDWernerUEckelJEnhanced protection against cytokine-and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analoguesHorm Metab Res200840317218018348079
   PubMed Web of Science ®Google Scholar
• BurcelinRGourdyPDalleSGLP-1-based strategies: a physiological analysis of differential mode of actionPhysiology (Bethesda)201429210812124583767
   PubMed Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin200824102943295218786299
   PubMed Web of Science ®Google Scholar
• PratleyRENauckMBaileyTLiraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialLancet201037597241447145620417856
   PubMed Web of Science ®Google Scholar
• AhrénBGomisRStandlEMillsDSchweizerATwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care200427122874288015562200
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetesDiabetes20075651475148017303799
   PubMed Web of Science ®Google Scholar
• HansotiaTDruckerDJGIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout miceRegul Peptides20051282125134
   PubMedGoogle Scholar
• WangTGouZWangFMaMZhaiSComparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studiesPLoS One201498e10379825089625
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLGuerciBExenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialLancet Diabetes Endocrinol20142646447324731672
   PubMed Web of Science ®Google Scholar
• GeorgeREJosephSA review of newer treatment approaches for type-2 diabetes: focusing safety and efficacy of incretin based therapySaudi Pharm J201422540341025473328
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnold ChanKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019102719278373
   PubMed Web of Science ®Google Scholar
• ElashoffMMatveyenkoAVGierBElashoffRButlerPCPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesGastroenterology2011141115015621334333
   PubMed Web of Science ®Google Scholar
• Bjerre KnudsenLMadsenLWAndersenSRGlucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferationEndocrinology201015141473148620203154
   PubMed Web of Science ®Google Scholar
• KornerMStockliMWaserBReubiJCGLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targetingJ Nucl Med200748573674317475961
   PubMed Web of Science ®Google Scholar
• WentenMGaeblerJAHusseinMRelative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up studyDiabetic Med201229111412141822416857
   PubMed Web of Science ®Google Scholar
• DeaconCFJohnsenAHHolstJJPeptide-l yields an N-terminally endogenous. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoJ Clin Endocrinol Metab19958039529577883856
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• JiLOnishiYAhnCWEfficacy and safety of exenatide once-weekly versus exenatide twice-daily in Asian patients with type 2 diabetes mellitusJ Diabetes Investig2013415361
   PubMed Web of Science ®Google Scholar
• StonehouseAWalshBCuddihyRExenatide once-weekly clinical development: safety and efficacy across a range of background therapiesDiabetes Technol Ther201113101063106921732798
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• DeYoungMBMacConellLSarinVTrautmannMHerbertPEncapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetesDiabetes Technol Ther201113111145115421751887
   PubMed Web of Science ®Google Scholar
• CaiYWeiLMaLLong-acting preparations of exenatideDrug Des Devel Ther20137963970
   PubMed Web of Science ®Google Scholar
• FinemanMFlanaganSTaylorKPharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingClin Pharmacokinet2011501657421142268
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet2010376973943143920580422
   PubMed Web of Science ®Google Scholar
• InagakiNAtsumiYOuraTSaitoHImaokaTEfficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority studyClin Ther20123491892190822884767
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab20119651301131021307137
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet201037597332234224320609969
   PubMed Web of Science ®Google Scholar
• BuseJBDruckerDJTaylorKLDURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksDiabetes Care20103361255126120215461
   PubMed Web of Science ®Google Scholar
• MeloniARDeYoungMBHanJBestJHGrimmMTreatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsCardiovasc Diabetol2013124823522121
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSSafety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeksDiabetes Care201235468368922357185
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• OnishiYKoshiyamaHImaokaTHaberHScism-BaconJBoardmanMKSafety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitusJ Diabetes Invest201342182189
   PubMed Web of Science ®Google Scholar
• BuseJBNauckMForstTExenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyLancet2013381986111712423141817
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• Russell-JonesDVaagASchmitzOLiraglutide versus insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia200952102046205519688338
   PubMed Web of Science ®Google Scholar
• MarreMShawJBrändleMLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)Diabetic Med200926326827819317822
   PubMed Web of Science ®Google Scholar
• SyedYYMcCormackPLExenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes MellitusDrugs201575101141115226071140
   PubMed Web of Science ®Google Scholar
• WyshamCGrimmMChenSOnce weekly exenatide: efficacy, tolerability and place in therapyDiabetes Obes Metab2013151087188123425609
   PubMed Web of Science ®Google Scholar
• FinemanMSShenLZTaylorKKimDDBaronADEffectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesDiabetes Metab Res Rev200420541141715343588
   PubMed Web of Science ®Google Scholar
• GiovannucciEHarlanDMArcherMCDiabetes and cancer: a consensus reportDiabetes Care20103371674168520587728
   PubMed Web of Science ®Google Scholar
• GuillerminALloydABestJHDeYoungMBSamyshkinYGaeblerJALong-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United StatesJ Med Econ201215465466322369345
   PubMedGoogle Scholar
• BeaudetAPalmerJLTimlinLCost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKJ Med Econ201114335736621563878
   PubMedGoogle Scholar
• SamyshkinYGuillerminALBestJHBrunellSCLloydALong-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USJ Med Econ201215Suppl 261322793669
   PubMedGoogle Scholar
• GaeblerJASoto-CamposGAlperinPHealth and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysisVasc Health Risk Manag2012825526422566747
   PubMedGoogle Scholar
• WangBRothJANguyenHFelberEFurnbackWGarrisonLPThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesPLoS One2015104e012191525849542
   PubMed Web of Science ®Google Scholar
• KimDMacConellLZhuangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care20073061487149317353504
   PubMed Web of Science ®Google Scholar